Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

Cyclin-dependent kinase inhibitors (CDKIs) and endocrine therapy (ET) are the corner-stone of systemic therapy for patients with hormone-positive (HR+) HER2-negative metastatic breast cancer (MBC). However, limited data exist regarding rechallenge treatment strategies with CDKIs after limiting toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuentes-Antrás, Jesús, de Luna, Alicia, López de Sá, Alfonso, Ocaña, Alberto, García-Sáenz, José Ángel, Moreno, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581964/
https://www.ncbi.nlm.nih.gov/pubmed/33096323
http://dx.doi.org/10.1016/j.breast.2020.10.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581964/
https://www.ncbi.nlm.nih.gov/pubmed/33096323
http://dx.doi.org/10.1016/j.breast.2020.10.007

Ejemplares similares